P. Brown

发表

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease

S. James, D. Erlinge, C. Varenhorst, 2014, Thrombosis and Haemostasis.

A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel

A. Kastrati, A. Schömig, B. Baker, 2013, Platelets.

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.

D. Foley, Junxiang Luo, S. James, 2012, Journal of the American College of Cardiology.

Prasugrel 5 mg inhibits platelet P-selectin and GPIIb–IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients

L. Truedsson, D. Erlinge, K. Winters, 2016, Journal of Thrombosis and Thrombolysis.

Novel findings from the multinational DOVE study on geographic and age‐related differences in pain perception and analgesic usage in children with sickle cell anaemia

D. Manwani, J. Jakubowski, J. Kanter, 2019, British journal of haematology.

Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients

S. James, D. Erlinge, D. Angiolillo, 2013, Journal of Thrombosis and Thrombolysis.

Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.

T. Lindahl, D. Foley, Junxiang Luo, 2013, Journal of the American College of Cardiology.

The Effect of Cyp2c19 Gene Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Prasugrel 5-mg, Prasugrel 10-mg and Clopidogrel 75-mg in Patients with Coronary Artery Disease Gurbel Cyp2c19 Genetics in Generations and Feather

T. Lindahl, S. James, D. Erlinge, 2022 .

Clinical trial conduct in special populations and developing regions: An overview of the DOVE study in pediatric patients with sickle cell disease.

K. Nanry, P. Brown, S. G. Reams, 2018, Contemporary clinical trials.

Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia

Brendan E. Smith, M. Heeney, D. Rees, 2016, Thrombosis and Haemostasis.

Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study

B. Ogutu, M. Heeney, D. Rees, 2016, Journal of clinical medicine.

Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia

S. Adjei, T. Agbenyega, M. Heeney, 2017, Clinical trials.

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

B. Ogutu, T. Agbenyega, M. Heeney, 2016, The New England journal of medicine.